GO:0009190 cyclic nucleotide biosynthetic process: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0009190 describes the biochemical reactions and pathways that produce cyclic nucleotides, which are nucleotides with the phosphate group in diester linkage to two positions on the sugar residue.
• Cyclic nucleotides such as cAMP and cGMP are universal second messengers that regulate ion channels, protein kinases, phosphodiesterases, and immune signaling.
• Key enzymes include adenylyl cyclases (ADCY1-10) and guanylyl cyclases (GUCY1A2, GUCY1B3, GUCY2C, etc.), which convert ATP and GTP into cAMP and cGMP, respectively.
• Cyclic nucleotide signaling is critical in cardiac hypertrophy, heart failure, retinal degeneration, and antiviral defense.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise dissection of cyclic nucleotide biosynthetic pathways in human cells and animal models.
• Research methods such as live-cell imaging, phosphodiesterase assays, and CRISPR library screening are essential to map the regulatory networks of cyclic nucleotide synthesis.
Description
Cyclic nucleotide biosynthetic process (GO:0009190) is a fundamental biological process that generates cyclic nucleotides, which are nucleotides in which the phosphate group forms a diester linkage to two positions on the sugar residue. These molecules, including cyclic AMP (cAMP) and cyclic GMP (cGMP), act as second messengers in diverse signaling cascades across prokaryotes, plants, and animals. The process is essential for translating extracellular signals into cellular responses, such as ion channel gating, kinase activation, and immune defense. Researchers study GO:0009190 because dysregulation of cyclic nucleotide synthesis underlies numerous human diseases, including cardiac hypertrophy, heart failure, retinal degeneration, and immune disorders. For example, cyclic nucleotide phosphodiesterases, which degrade cAMP and cGMP, are therapeutic targets in heart failure. Moreover, cyclic nucleotide-activated CRISPR proteases in bacteria have revealed novel antiviral signaling mechanisms. Understanding the biosynthetic machinery is therefore critical for developing targeted therapies. The process is mediated by adenylyl and guanylyl cyclases, which catalyze the cyclization of ATP and GTP, respectively. These enzymes are regulated by diverse inputs, including G-protein coupled receptors, calcium, and nitric oxide. In plants, cyclic nucleotide interactomes have been mapped, revealing conserved and unique components. Structural studies of cyclic nucleotide-gated channels have provided insights into discrimination between cAMP and cGMP. This article synthesizes current knowledge on GO:0009190, its genes, regulation, disease relevance, and research methods.
cyclic nucleotide biosynthetic process At A Glance
| GO ID | GO:0009190 |
|---|---|
| GO term | cyclic nucleotide biosynthetic process |
| Ontology | biological_process |
| Synonym | cyclic nucleotide anabolism; cyclic nucleotide biosynthesis; cyclic nucleotide formation; cyclic nucleotide synthesis |
| Major function | Production of cyclic nucleotides (cAMP, cGMP) as second messengers |
| Key enzymes | Adenylyl cyclases (ADCY1-10), guanylyl cyclases (GUCY1A2, GUCY1B3, GUCY2C, etc.) |
| Substrates | ATP, GTP |
| Products | cAMP, cGMP, other cyclic nucleotides |
| Related processes | Signal transduction, ion channel regulation, immune response |
What Is GO:0009190?
GO:0009190, cyclic nucleotide biosynthetic process, is defined as the chemical reactions and pathways resulting in the formation of a cyclic nucleotide, a nucleotide in which the phosphate group is in diester linkage to two positions on the sugar residue. This process includes the enzymatic conversion of nucleoside triphosphates (e.g., ATP, GTP) into cyclic monophosphates (e.g., cAMP, cGMP) by cyclases, as well as any subsequent modifications that yield other cyclic nucleotides. It is a biological process ontology term that encompasses anabolism, biosynthesis, formation, and synthesis of cyclic nucleotides.
Why Is cyclic nucleotide biosynthetic process Important in Cell Biology?
Cyclic nucleotide biosynthetic process is vital because cyclic nucleotides serve as universal second messengers that regulate a vast array of physiological functions, including cardiac contractility, neuronal signaling, immune responses, and vision. Dysregulation of this process contributes to major human diseases such as heart failure, retinal degeneration, and inflammatory disorders. Additionally, bacterial cyclic nucleotide-activated CRISPR proteases highlight its role in antiviral defense. Understanding the biosynthetic pathways offers opportunities for therapeutic intervention and biotechnological applications.
• Cyclic nucleotides are essential second messengers in signal transduction across all domains of life.
• Adenylyl and guanylyl cyclases are drug targets for cardiovascular diseases, including heart failure and hypertension.
• Cyclic nucleotide phosphodiesterases modulate cAMP/cGMP levels and are therapeutic targets in cardiac hypertrophy.
• Cyclic nucleotide-gated ion channels are critical for vision and olfaction; mutations cause retinal degeneration.
• Cyclic nucleotide signaling regulates immune cell function and inflammation, with pharmacological potential.
• Bacterial cyclic nucleotide-activated CRISPR proteases provide antiviral immunity, linking to biotechnology.
• Plant cyclic nucleotide interactomes reveal roles in development and stress responses.
• Structural insights into cyclic nucleotide discrimination aid design of selective modulators.
• Cyclic nucleotide biosynthetic enzymes are conserved from bacteria to humans, enabling model organism studies.
• CRISPR screening can identify novel regulators of cyclic nucleotide synthesis for therapeutic targeting.
What Happens During cyclic nucleotide biosynthetic process?
Substrate Binding and Cyclase Activation
In simple terms: The process starts when an enzyme grabs ATP or GTP and prepares to bend it into a ring.
Adenylyl cyclases and guanylyl cyclases bind their respective substrates, ATP and GTP, in the active site. This binding is often regulated by G-proteins, calcium, or nitric oxide. For example, membrane-bound adenylyl cyclases are activated by Gs-alpha subunits, while soluble guanylyl cyclases are activated by nitric oxide. The binding induces conformational changes that position the substrate for cyclization.
Catalytic Cyclization to Form cAMP or cGMP
In simple terms: The enzyme cuts off two phosphates and joins the remaining phosphate to the sugar in a loop, making cAMP or cGMP.
The cyclase catalyzes the intramolecular attack of the 3'-hydroxyl group on the alpha-phosphate of the nucleoside triphosphate, releasing pyrophosphate and forming the cyclic 3',5'-phosphodiester bond. This reaction yields cAMP from ATP or cGMP from GTP. The catalytic mechanism involves two metal ions (typically Mg2+ or Mn2+) that stabilize the transition state. Structural studies of cyclic nucleotide-gated channels have revealed how cyclic nucleotides are discriminated, which informs cyclase product specificity.
Product Release and Downstream Signaling
In simple terms: The newly made cAMP or cGMP is released and goes on to activate other proteins.
Once formed, cyclic nucleotides are released from the cyclase and bind to effector proteins such as protein kinase A (PKA), protein kinase G (PKG), cyclic nucleotide-gated ion channels, and exchange proteins activated by cAMP (EPAC). This binding triggers downstream signaling cascades, including phosphorylation, ion flux, and gene expression changes. In immune cells, cyclic nucleotides modulate inflammatory responses.
Regulation by Phosphodiesterases and Feedback
In simple terms: Other enzymes break down cAMP and cGMP to keep their levels balanced.
Cyclic nucleotide phosphodiesterases (PDEs) hydrolyze cAMP and cGMP to AMP and GMP, respectively, providing a counterbalance to synthesis. This regulation is crucial for maintaining spatial and temporal signaling specificity. In cardiac hypertrophy and heart failure, PDEs are therapeutic targets because their inhibition elevates cyclic nucleotide levels and improves contractility. Feedback mechanisms also exist at the level of cyclase expression and activity.
Compartmentalization and Interactome
In simple terms: The enzymes and their products are not floating freely; they are organized in specific cellular locations.
Cyclic nucleotide signaling is highly compartmentalized, with cyclases, PDEs, and effectors anchored to specific subcellular structures such as membranes, nuclei, and cytoskeleton. The Arabidopsis cyclic nucleotide interactome has been mapped, revealing protein-protein interaction networks that regulate synthesis and response. In mammalian cells, A-kinase anchoring proteins (AKAPs) tether PKA and PDEs to ensure localized signaling.
Key Genes Involved in GO:0009190 cyclic nucleotide biosynthetic process
The following genes encode enzymes and regulators directly involved in cyclic nucleotide biosynthetic process (GO:0009190).
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADCY1 | Adenylyl cyclase 1, converts ATP to cAMP | Neuronal signaling, memory formation; knockout models show learning deficits |
| ADCY2 | Adenylyl cyclase 2, cAMP synthesis | Cardiac and neuronal function; target for heart failure |
| ADCY3 | Adenylyl cyclase 3, cAMP synthesis | Olfaction, obesity; knockout mice are obese |
| ADCY5 | Adenylyl cyclase 5, cAMP synthesis | Cardiac contractility; mutations linked to dyskinesia |
| ADCY6 | Adenylyl cyclase 6, cAMP synthesis | Cardiac and vascular function; knockout reduces heart failure |
| ADCY8 | Adenylyl cyclase 8, cAMP synthesis | Learning and memory; calcium-stimulated |
| ADCY9 | Adenylyl cyclase 9, cAMP synthesis | Immune regulation; asthma susceptibility |
| ADCY10 | Soluble adenylyl cyclase, cAMP synthesis | Sperm motility, bicarbonate sensing |
| GUCY1A2 | Guanylyl cyclase subunit alpha-2, cGMP synthesis | Cardiovascular function; target for hypertension |
| GUCY1B3 | Guanylyl cyclase subunit beta-3, cGMP synthesis | Nitric oxide signaling; knockout affects smooth muscle |
| GUCY2C | Guanylyl cyclase C, cGMP synthesis | Intestinal homeostasis; target for colorectal cancer |
| GUCY2D | Retinal guanylyl cyclase, cGMP synthesis | Vision; mutations cause Leber congenital amaurosis |
| GUCY2F | Retinal guanylyl cyclase F, cGMP synthesis | Phototransduction; role in retinal degeneration |
| PDE1A | Phosphodiesterase 1A, degrades cAMP/cGMP | Cardiac hypertrophy; therapeutic target |
| PDE2A | Phosphodiesterase 2A, degrades cAMP/cGMP | Neuronal signaling; target for cognitive disorders |
| PDE3A | Phosphodiesterase 3A, degrades cAMP/cGMP | Heart failure; inhibition improves contractility |
| PDE5A | Phosphodiesterase 5A, degrades cGMP | Erectile dysfunction, pulmonary hypertension; target of sildenafil |
| PRKACA | Protein kinase A catalytic subunit, effector of cAMP | cAMP signaling; mutations cause Cushing's syndrome |
How Is cyclic nucleotide biosynthetic process Regulated?
Cyclic nucleotide biosynthetic process is tightly regulated at multiple levels. Adenylyl cyclases are regulated by G-protein coupled receptors (GPCRs) via Gs and Gi subunits, calcium/calmodulin, and phosphorylation. Guanylyl cyclases are regulated by nitric oxide, natriuretic peptides, and calcium. Phosphodiesterases provide negative feedback by hydrolyzing cyclic nucleotides, and their activity is modulated by cGMP binding and phosphorylation. In plants, cyclic nucleotide levels are influenced by environmental stimuli and interactome components. Additionally, bacterial cyclic nucleotide-activated CRISPR proteases are regulated by cyclic nucleotides to trigger antiviral defense.
cyclic nucleotide biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GUCY2D | Leber congenital amaurosis, retinal degeneration | Knock-in mouse with patient mutation; retinal organoids |
| PDE3A | Heart failure, cardiac hypertrophy | Cardiomyocyte-specific knockout; overexpression in mouse heart |
| GUCY2C | Colorectal cancer, intestinal homeostasis | Knockout mouse; human colon cancer cell lines |
| ADCY5 | Dyskinesia, diabetes | Point mutation knock-in mouse; patient-derived iPSCs |
| PDE5A | Pulmonary hypertension, erectile dysfunction | Knockout mouse; smooth muscle cell models |
Cardiovascular Disease
Dysregulation of cyclic nucleotide biosynthetic process is central to cardiac hypertrophy and heart failure. Reduced cAMP and cGMP signaling contributes to pathological remodeling, and phosphodiesterase inhibitors that elevate cyclic nucleotides are used therapeutically. For example, PDE3A inhibition increases cAMP and improves contractility in heart failure. Guanylyl cyclase activators are also explored for hypertension.
Retinal Degeneration
Mutations in GUCY2D and GUCY2F, which encode retinal guanylyl cyclases, impair cGMP synthesis and cause Leber congenital amaurosis and other retinal dystrophies. Cyclic nucleotide-gated channels in photoreceptors require cGMP for opening; disrupted synthesis leads to vision loss. Calmodulin regulation of these channels is critical for adaptation.
Immune Disorders and Inflammation
Cyclic nucleotide signaling modulates immune cell activation, cytokine production, and inflammation. Pharmacological manipulation of cAMP and cGMP pathways has potential in autoimmune diseases and chronic inflammation. For instance, PDE4 inhibitors increase cAMP and reduce inflammatory responses. Bacterial cyclic nucleotide-activated CRISPR proteases also link cyclic nucleotides to antiviral immunity.
Cancer
Cyclic nucleotide signaling is implicated in cancer cell proliferation, apoptosis, and metastasis. GUCY2C, a guanylyl cyclase, acts as a tumor suppressor in colorectal cancer, and its loss promotes tumorigenesis. Targeting cyclic nucleotide pathways is being explored for cancer therapy.
From cyclic nucleotide biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ADCY1 affect neuronal cAMP levels? | ADCY1 knockout mouse or human iPSC-derived neurons |
| How does a point mutation in GUCY2D alter cGMP synthesis? | Knock-in mouse carrying patient mutation; retinal explants |
| Can overexpression of PDE3A rescue heart failure? | Cardiomyocyte-specific overexpression in mouse |
| What is the interactome of cyclic nucleotide enzymes? | Tagged knock-in of ADCY or GUCY in Arabidopsis or human cells |
| Which genes regulate cyclic nucleotide levels in immune cells? | CRISPR library screening in macrophage cell lines |
| How does cyclic nucleotide-activated CRISPR protease respond to cGMP? | Bacterial knockout and point mutation models |
How to Study the cyclic nucleotide biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| FRET biosensors | Real-time cAMP/cGMP concentration | Live-cell imaging of signaling dynamics |
| PDE activity assay | Phosphodiesterase hydrolysis rate | Drug screening for PDE inhibitors |
| CRISPR knockout screening | Gene essentiality for cyclic nucleotide levels | Identifying novel regulators in immune cells |
| RNA-seq | Transcriptional changes in cyclases/PDEs | Response to stimuli or disease models |
| Proteomics | Protein interactions and post-translational modifications | Mapping cyclic nucleotide interactome |
| Patch-clamp electrophysiology | Ion channel activity gated by cyclic nucleotides | Retinal rod/cone function |
| X-ray crystallography | Three-dimensional structure of cyclases | Mechanistic studies and drug design |
Live-Cell Imaging of Cyclic Nucleotide Dynamics
Genetically encoded FRET sensors (e.g., Epac-based cAMP sensors, cGMP sensors) allow real-time visualization of cyclic nucleotide levels in living cells. These sensors can be targeted to specific compartments to study localized synthesis.
Phosphodiesterase Activity Assays
PDE activity is measured using radiolabeled cAMP/cGMP or fluorescent substrates to determine hydrolysis rates. This is critical for understanding the balance between synthesis and degradation.
CRISPR Library Screening
Genome-wide CRISPR knockout or activation screens can identify genes that regulate cyclic nucleotide levels or downstream signaling. For example, screens in immune cells have revealed modulators of cAMP pathways.
Structural Biology and Biophysics
X-ray crystallography and cryo-EM of cyclases and cyclic nucleotide-gated channels reveal substrate binding and catalytic mechanisms. These studies inform drug design.
How CRISPR Can Be Used to Study GO:0009190 cyclic nucleotide biosynthetic process
Knockout
CRISPR knockout of adenylyl or guanylyl cyclase genes (e.g., ADCY1, GUCY2D) abolishes cyclic nucleotide synthesis, enabling loss-of-function studies in cell lines and animal models. For example, ADCY3 knockout mice exhibit obesity, linking cAMP to metabolic regulation.
Point Mutation
Introducing patient-specific point mutations (e.g., in GUCY2D or ADCY5) via CRISPR base editing or HDR recapitulates disease phenotypes and reveals structure-function relationships. Such models are valuable for testing targeted therapies.
Knock-in
Knock-in of tagged cyclases (e.g., GFP-ADCY6) allows visualization and purification of native complexes. Knock-in of disease mutations (e.g., GUCY2C variants) creates isogenic models for cancer research.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of cyclases or PDEs elevates or reduces cyclic nucleotide levels, respectively. Overexpression of PDE3A in cardiomyocytes mimics heart failure and tests rescue strategies.
How EDITGENE Supports cyclic nucleotide biosynthetic process Research
Researchers studying cyclic nucleotide biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in cyclic nucleotide synthesis, signaling, or disease. EDITGENE provides comprehensive CRISPR services to generate precisely engineered cell models, enabling functional validation and drug discovery.
Contact EDITGENE today to design your custom CRISPR model for cyclic nucleotide biosynthetic process research.
Frequently Asked Questions About cyclic nucleotide biosynthetic process
What is cyclic nucleotide biosynthetic process?
It is the biological process (GO:0009190) that produces cyclic nucleotides such as cAMP and cGMP, which act as second messengers.
What genes are involved in cyclic nucleotide biosynthetic process?
Key genes include adenylyl cyclases (ADCY1-10), guanylyl cyclases (GUCY1A2, GUCY1B3, GUCY2C, GUCY2D), and phosphodiesterases (PDE1A, PDE2A, PDE3A, PDE5A).
How is cAMP synthesized?
Adenylyl cyclases convert ATP to cAMP by cyclization, releasing pyrophosphate.
What is the role of cGMP in vision?
cGMP is essential for phototransduction; mutations in retinal guanylyl cyclases cause retinal degeneration.
Which diseases are linked to cyclic nucleotide synthesis?
Cardiac hypertrophy, heart failure, retinal degeneration, immune disorders, and colorectal cancer.
How can CRISPR be used to study cyclic nucleotide synthesis?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional dissection of cyclase and PDE genes.
What are phosphodiesterases?
Enzymes that degrade cAMP and cGMP, providing negative regulation of cyclic nucleotide signaling.
What methods measure cyclic nucleotide levels?
FRET biosensors, PDE activity assays, and mass spectrometry.
Is cyclic nucleotide signaling conserved in plants?
Yes, plants have cyclic nucleotide interactomes and signaling components.
What is the role of cyclic nucleotides in immunity?
They modulate immune cell activation and inflammation, with pharmacological potential.
Conclusion
Cyclic nucleotide biosynthetic process (GO:0009190) is a central signaling pathway that produces cAMP and cGMP, regulating diverse physiological and pathological processes. Key enzymes such as adenylyl and guanylyl cyclases, along with phosphodiesterases, are attractive therapeutic targets in cardiovascular, retinal, and immune diseases. CRISPR-based models are indispensable for dissecting these pathways and validating drug targets. EDITGENE provides end-to-end CRISPR services to accelerate research on cyclic nucleotide synthesis and signaling.
References
- 1. Biel M. 2009. Cyclic nucleotide-regulated cation channels.. J Biol Chem 284(14):9017-21 PMID: 19054768
- 2. Kamel R et al.. 2023. Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure.. Nat Rev Cardiol 20(2):90-108 PMID: 36050457
- 3. Rouillon C et al.. 2023. Antiviral signalling by a cyclic nucleotide activated CRISPR protease.. Nature 614(7946):168-174 PMID: 36423657
- 4. Ednacot EMQ et al.. 2024. Pharmacological potential of cyclic nucleotide signaling in immunity.. Pharmacol Ther 258:108653 PMID: 38679204
- 5. Newton RP et al.. 2004. Cyclic nucleotides.. Phytochemistry 65(17):2423-37 PMID: 15381406
- 6. Donaldson L et al.. 2016. The arabidopsis cyclic nucleotide interactome.. Cell Commun Signal 14(1):10 PMID: 27170143
- 7. Pan Y et al.. 2023. Discrimination between cyclic nucleotides in a cyclic nucleotide-gated ion channel.. Nat Struct Mol Biol 30(4):512-520 PMID: 36973509
- 8. Bej A et al.. 2022. Retinal Cyclic Nucleotide-Gated Channel Regulation by Calmodulin.. Int J Mol Sci 23(22) PMID: 36430626
